Heart Failure Can't Cured but Could Reduced
Heart Failure Can't Cured but Could Reduced
A
A
A
JAKARTA - Indonesia and other nations in Southeast Asia are shown to have a high enough risk of heart failure compared to other nations in the world. Unfortunately, misconceptions about heart failure among Indonesians often occur and less healthy lifestyles such as rarely exercising, inappropriate eating habits and smoking are still a daily life undertaken.
"Heart failure can not be cured, therefore it is very important for people to be more aware of this disease and know the symptoms for people with heart failure can have a more active and long life," said Prof. Dr. Bambang Budi Siswanto from Harapan Kita Heart Center Hospital in Jakarta on Saturday (29/7).
Compared with residents in western countries, heart failure patients in Southeast Asia occurs at a younger age and is characterized by more severe clinical conditions, with vascular risk factors such as hypertension, obesity and diabetes. Consistently over a decade, heart failure patients in Asia have proven to be younger than patients in Europe.
The heart is one of the most important organs, but sometimes people tend to ignore symptoms that imply that their heart is in trouble. Heart failure is a serious chronic condition when the heart can no longer pump enough blood to meet the body's oxygen demand due to weakening of the heart muscle over time. It can affect every individual in all ages.
Studies also show that the quality of life of patients with heart failure is worse than other chronic conditions. This interferes with the patient to perform simple tasks and participate in daily activities with friends and family-statistics show that 76 percent of patients struggling to perform activities of daily living after a diagnosis of heart failure.
Globally, the increased live load of heart failure puts a very heavy burden on people, especially on patients, caregivers and health insurance systems. The economic burden caused by heart failure, in large part, comes from the frequency and length of hospitalization for patients. Caregiver also wins high emotional, physical and financial burdens when they care for family members who suffer from heart failure.
![Heart Failure Can't Cured but Could Reduced]()
To find solutions to this disease, pharmaceutical companies such as Novartis, are actively making discoveries that bring medical treatment in a new direction.
"In order to reduce the deterioration of heart failure patients, Novartis presents treatment of heart failure LCZ696 named molecule sacubitril valsartan sodium hydrate in treatment classes Arni (Angiotensin Receptor-Neprilysin inhibitor) in Indonesia, since it was first launched in Europe and United States (US) in 18 months ago," said President Director of Novartis Indonesia, Milan Paleja.
He said, Novartis commitment remains firm in all the countries in which they operate. In Indonesia, Novartis is also always ready to support the Indonesian government and work with all stakeholders to assist Indonesian patients suffering from cardio-metabolic diseases, such as diabetes, hypertension and heart failure, either through JKN or the commercial market.
"With this, we also hope to help alleviate the social and economic burden as a result of this disease It is a pride for us to be able to work with the Indonesian Cardiovascular Specialist Association (PERKI) and other stakeholders to reach more patients in Indonesia," said Milan.
"Heart failure can not be cured, therefore it is very important for people to be more aware of this disease and know the symptoms for people with heart failure can have a more active and long life," said Prof. Dr. Bambang Budi Siswanto from Harapan Kita Heart Center Hospital in Jakarta on Saturday (29/7).
Compared with residents in western countries, heart failure patients in Southeast Asia occurs at a younger age and is characterized by more severe clinical conditions, with vascular risk factors such as hypertension, obesity and diabetes. Consistently over a decade, heart failure patients in Asia have proven to be younger than patients in Europe.
The heart is one of the most important organs, but sometimes people tend to ignore symptoms that imply that their heart is in trouble. Heart failure is a serious chronic condition when the heart can no longer pump enough blood to meet the body's oxygen demand due to weakening of the heart muscle over time. It can affect every individual in all ages.
Studies also show that the quality of life of patients with heart failure is worse than other chronic conditions. This interferes with the patient to perform simple tasks and participate in daily activities with friends and family-statistics show that 76 percent of patients struggling to perform activities of daily living after a diagnosis of heart failure.
Globally, the increased live load of heart failure puts a very heavy burden on people, especially on patients, caregivers and health insurance systems. The economic burden caused by heart failure, in large part, comes from the frequency and length of hospitalization for patients. Caregiver also wins high emotional, physical and financial burdens when they care for family members who suffer from heart failure.
To find solutions to this disease, pharmaceutical companies such as Novartis, are actively making discoveries that bring medical treatment in a new direction.
"In order to reduce the deterioration of heart failure patients, Novartis presents treatment of heart failure LCZ696 named molecule sacubitril valsartan sodium hydrate in treatment classes Arni (Angiotensin Receptor-Neprilysin inhibitor) in Indonesia, since it was first launched in Europe and United States (US) in 18 months ago," said President Director of Novartis Indonesia, Milan Paleja.
He said, Novartis commitment remains firm in all the countries in which they operate. In Indonesia, Novartis is also always ready to support the Indonesian government and work with all stakeholders to assist Indonesian patients suffering from cardio-metabolic diseases, such as diabetes, hypertension and heart failure, either through JKN or the commercial market.
"With this, we also hope to help alleviate the social and economic burden as a result of this disease It is a pride for us to be able to work with the Indonesian Cardiovascular Specialist Association (PERKI) and other stakeholders to reach more patients in Indonesia," said Milan.
(rnz)
Explore More